AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $229.50 billion. The enterprise value is $254.76 billion.
Important Dates
The last earnings date was Thursday, February 6, 2025, before market open.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | Feb 21, 2025 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 32.62 and the forward PE ratio is 16.53.
| PE Ratio | 32.62 |
| Forward PE | 16.53 |
| PS Ratio | 4.24 |
| Forward PS | 3.95 |
| PB Ratio | 5.62 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 23.10 |
| P/OCF Ratio | 19.35 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.50, with an EV/FCF ratio of 25.64.
| EV / Earnings | 36.21 |
| EV / Sales | 4.71 |
| EV / EBITDA | 14.50 |
| EV / EBIT | 19.70 |
| EV / FCF | 25.64 |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.75.
| Current Ratio | 0.93 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 1.70 |
| Debt / FCF | 3.07 |
| Interest Coverage | 9.22 |
Financial Efficiency
Return on equity (ROE) is 17.59% and return on invested capital (ROIC) is 11.53%.
| Return on Equity (ROE) | 17.59% |
| Return on Assets (ROA) | 7.88% |
| Return on Invested Capital (ROIC) | 11.53% |
| Return on Capital Employed (ROCE) | 16.97% |
| Revenue Per Employee | $582,056 |
| Profits Per Employee | $75,727 |
| Employee Count | 92,900 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.80 |
Taxes
In the past 12 months, AstraZeneca has paid $1.65 billion in taxes.
| Income Tax | 1.65B |
| Effective Tax Rate | 18.99% |
Stock Price Statistics
The stock price has increased by +14.11% in the last 52 weeks. The beta is 0.20, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | +14.11% |
| 50-Day Moving Average | 68.72 |
| 200-Day Moving Average | 74.99 |
| Relative Strength Index (RSI) | 64.26 |
| Average Volume (20 Days) | 5,343,656 |
Short Selling Information
| Short Interest | 16.94M |
| Short Previous Month | 15.10M |
| Short % of Shares Out | 0.55% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.62 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $54.07 billion and earned $7.04 billion in profits. Earnings per share was $4.50.
| Revenue | 54.07B |
| Gross Profit | 44.44B |
| Operating Income | 12.93B |
| Pretax Income | 7.74B |
| Net Income | 7.04B |
| EBITDA | 17.57B |
| EBIT | 12.93B |
| Earnings Per Share (EPS) | $4.50 |
Full Income StatementBalance Sheet
The company has $5.53 billion in cash and $30.46 billion in debt, giving a net cash position of -$24.94 billion or -$16.08 per share.
| Cash & Cash Equivalents | 5.53B |
| Total Debt | 30.46B |
| Net Cash | -24.94B |
| Net Cash Per Share | -$16.08 |
| Equity (Book Value) | 40.87B |
| Book Value Per Share | 26.30 |
| Working Capital | -2.04B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $11.86 billion and capital expenditures -$1.92 billion, giving a free cash flow of $9.94 billion.
| Operating Cash Flow | 11.86B |
| Capital Expenditures | -1.92B |
| Free Cash Flow | 9.94B |
| FCF Per Share | $6.41 |
Full Cash Flow StatementMargins
Gross margin is 82.18%, with operating and profit margins of 23.91% and 13.01%.
| Gross Margin | 82.18% |
| Operating Margin | 23.91% |
| Pretax Margin | 16.07% |
| Profit Margin | 13.01% |
| EBITDA Margin | 32.49% |
| EBIT Margin | 23.91% |
| FCF Margin | 18.38% |
Dividends & Yields
This stock pays an annual dividend of $1.52, which amounts to a dividend yield of 2.05%.
| Dividend Per Share | $1.52 |
| Dividend Yield | 2.05% |
| Dividend Growth (YoY) | 4.83% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 33.78% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 1.98% |
| Earnings Yield | 3.07% |
| FCF Yield | 4.33% |
Dividend DetailsAnalyst Forecast
The average price target for AstraZeneca is $89.75, which is 20.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $89.75 |
| Price Target Difference | 20.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 6.92% |
| EPS Growth Forecast (5Y) | 10.24% |
Stock ForecastsStock Splits
The last stock split was on July 27, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2015 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
AstraZeneca has an Altman Z-Score of 3.15 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.15 |
| Piotroski F-Score | 6 |